Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
What if the shorts abandoned IPIX and went after a weak kneed un IND ed other company? Tables may be turned!
Here Today, Ol Mr Cramer may be in it up to his armpits to, leading his lemmings right down to the short attack den:
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds NanoViricides (NNVC) Investors of Proprietary Investigation into Possible Securities Law Violations, Encourages Investors and Persons Who May be Able to Assist Investigation to Contact Firm
https://www.globenewswire.com/news-release/2020/07/20/2064629/0/en/HAGENS-BERMAN-NATIONAL-TRIAL-ATTORNEYS-Reminds-NanoViricides-NNVC-Investors-of-Proprietary-Investigation-into-Possible-Securities-Law-Violations-Encourages-Investors-and-Persons-Wh.html
News headline that drove stock price today:
NanoViricides, Inc. Pan-coronavirus Clinical Drug Candidates for the Treatment of COVID-19 Are Highly Effective in Pre-clinical Cell Culture Studies Performed in Preparation of FDA Pre-IND Application
PJ007, Totally agree this next PR will be the one heard around the world! JMO
You may want to add in the new strains and those who have taken the vaccine becoming re-infected.
I believe this is the prelude to a string of future BLOCK BUSTER news releases and with that belief I put another order in and filled @ .32.
Link to article published in MDPI:
Open AccessArticle
Brilacidin Demonstrates Inhibition of SARS-CoV-2 in Cell Culture
https://www.mdpi.com/1999-4915/13/2/271/htm
dp70 Astrology date upcoming:
March 8 through March 10 – this could be very public news that trial has actually ended with improvement in patients. If so, then this could increase sp (unable to speculate how much) and the company having access to more money for a third trial.
Has antone tried to log in to the CPAC web site? My computer shows that I am directed to Seattle and blocked there. https://cpac.conservative.org
Just like Kevetrin, P53 endless possibilities.
Basil22, I like your thinking fact is Brilacidin was designed for a multitude of ailments.
It would be interesting to discover the side effects it has on people who have diverticulitis and other IBD problems.Will they investigate?
I would prefer an order for a 1oo million dosage series to a buyout, as to the inhalent, immediate trials ASAP.
You make so many great points: "I believe the difference in Leo and your thinking is that Leo isn't willing to give up many billions of dollars of value for a few billion in return."
I HAPPEN TO BE THINKING EXACTLY WHAT YOU SAY LEO IS THINKING.
The point we are at:
*Mpnday March 1,2021 we will be in the 5th week, following Leo's announcement, when the trials were to begin.
* Topline results could be released at any minute after today.
* All we need is confirmation that Brilacidin preformed as expected.
* It should not be a surprise that an immediate EUA would be approved.
* The United States alone could order from 100 to 200 million treatment series of Brilacidin, representing from 100 Billion to 200 Billion dollars, possible more.
* How many countries worlwide will want to stock Brilacidin? I would suggest just about every country. No way to estimate a number for the dosages needed.
*But the USA alone would drive the share price into the Stratissphere. If the order was for a hundred billion dollars and the cost of manufacturing, distribution and overhead was 70% that would leave a profit of 30 Billion dollars, or Approximately $2.50 X 30 = $90.00 per share. Extrolapate that out and add orders from all the other countries.
I am not for selling Innovation Pharmaceuticals but, If Leo decided to sell, it "wouldd not" be for chickenfeed, he knows what we have and the value.
If Brilacidin wasn't showing Effacacy at this point I believe the trials would have been cancelled.
*Also, how about that phase 3 Remdesivir trial: "This open-label study evaluated 5-day and 10-day courses of the investigational antiviral remdesivir plus standard of care, versus standard of care alone".
Just my Opinion!
EXACTLY PETE, THough my expertese is in Real Real Estate and I know little about the Pharmaceutical Industry only investing in four pharmaceutical companies, over the years I've been investing, I know that Brilacidin will be valued just like Real Estate, by the amount of future revenues it produces and Brilacidin's future revenue will be measured, not just IN Billions but in the 100's of billions when all of the Indications and off label uses are included. After a few more "days" we can quit guessing we will know the potential, no more speculating. I know how to evaluate an income stream /cash flow, discounted future value etc. Those are what creates "SHARE" value!
You don't believe a Phase 2 and an EUA would garner attention? Gilead's Remdesivir has brought in 150 billion during the last year as a result of being approved for the EUA, for Rendesivir, but Brilacidin is practically worthless according to many posters, until it goes through the phase 3 trials? I don't subscribe to that.I believe Brilacidin would be a multi-billion dollar company as soon as Brilacidin is recognized as a top line Therapeutic for Covid 19, I don't believe Gilead would hesitate to pay Billions for Brilacidin if they think they could leverege the product like they have with Remdesivir. Take a look at the Phase 3 Remdesivir if you want to see what their phase 3 trial looked like. Anyone want to calculate what the discounted future value for IPIX would be if it preforms as expected?
https://www.gilead.com/news-and-press/press-room/press-releases/2020/6/gilead-announces-results-from-phase-3-trial-of-remdesivir-in-patients-with-moderate-covid-19
"FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced topline results from the Phase 3 SIMPLE trial in hospitalized patients with moderate COVID-19 pneumonia. This open-label study evaluated 5-day and 10-day courses of the investigational antiviral remdesivir plus standard of care, versus standard of care alone. The study demonstrated that patients in the 5-day remdesivir treatment group were 65 percent more likely to have clinical improvement at Day 11 compared with those in the standard of care group (OR 1.65 [95% CI 1.09-2.48]; p=0.017). The odds of improvement in clinical status with the 10-day treatment course of remdesivir versus standard of care were also favorable, trending toward but not reaching statistical significance (OR 1.31 [95% CI 0.88-1.95]; p=0.18). No new safety signals were identified with remdesivir across either treatment group. Gilead plans to submit the full data for publication in a peer-reviewed journal in the coming weeks."
Of particular note, overall viral load was reduced by 99.85 percent in one combination experiment, with remaining virus dropping to near undetectable levels.
https://finance.yahoo.com/news/laboratory-testing-brilacidin-covid-19-130000483.html
My take on the PR milestone, next PR could very well make many IHUB participants millionaires and in some cases multimillionaires. We have reached the point of calling for the "RIVER CARD" as in Texas Hold'em.
dp70's 3 predictions, today was the first:
Feb 28 – possible news about status of trial and possible news regarding foreign trial or dealings with foreigners regarding B. (Mars in 9th house rules publications, dealings with foreign countries). The money prospects of the company steadily increase through March which could be in the form of grants, collaborations, increase in stockholders.
March 8 through March 10 – this could be very public news that trial has actually ended with improvement in patients. If so, then this could increase sp (unable to speculate how much) and the company having access to more money for a third trial.
March 13 – the company could be compiling the data from the trial results and with Mercury (rules data and information) in positive aspect to Pluto (the trial). This data could possibly mean a PR about results.
MackG, NEXT PR, LEO, KICKS FUDSTERS TO THE CURB!!
Mr40 there are lots of things that will dissappear under the Biden /Globalist communist democrats and others that be ignored. Under the gun control bill 105 million Law abiding Citizens will instantly become Law breakers and subject to prosecution. Its the dictators way.
Mr40 there are lots of things that will dissappear under the Biden /Globalist communist democrats and others that be ignored. Under the gun control bill 105 million Law abiding Citizens will instantly become Law breakers and subject to prosecution. Its the dictators way.
WE have just experienced a seditionist Coup by the Globalist, Communist democrats, MSM'S, assisted by the electronic Giants, so called "Social Media" they are enemies just as China, Russia and the Islamist who are commited to world domination. Using the weapons of electronic warfare, don't doubt it, we have lost a battle to the Globalist, we must work to reverse the results and to win the war against America. Donald Trump won the election and is the truly elected president.
Like your thinking, soon!
If true? Would the "botch" have stopped Leo if the stock price hadn't been driven into the ground by MAKO, would Leo have revamped and submitted the application? Guess we will never know!
If you would like to do some DD, yu will find that Leo was in the process of up listing when the MAKO thugs decided to take us out.
The top hand in poker is a Ace high straight flush in spades, AKA, Royal flush, Leo may not be holding that hand, but he sure as hell has 4 Ace's.
Yeah here is an example of what they post:
Tripstockd Tuesday, 02/23/21 11:52:30 PM
Re: None 0
Post #
348573
of 348645
F Leo
Got this from a friend and IPIX investor: .imo...you are absolutely correct:
Quote:
The Captain of our ship is Leo Ehrlich whom we rely on to steer us to reap the rewards of a successful Brilacidin trial for COVID-19. That’s right the same drug he bought for $5million.
...an astute and some would say "genius" move!
Leo's new "stealth" approach to releasing minimal information (via disclosure in 10Q) could be pointing (speculating) to another...ASTUTE MOVE...and more positive news on the horizon.
The question becomes what has caused Leo to radically modify his M.O. ... not doing a traditional expansive PR, on obviously good news (commencement of trials in U.S. and Russia). The anwer might be in four questions...
1. Could the LEO M.O change due to stategic calculated shift? Likely...another clever move...Keep the details close to the vest...and naked and legal shorts in the dark...until BOOM! Brilacidin explodes onto the scene...OK good...but there could be more..
2. Could the regulatory authority (FDA) desire to keep the information on trial developments and their results...under wraps because they know how explosive and fundamentally ground-breaking in the treatment of all viruses and bacteria?
3. Could IPIX be in a quiet period by agreemengt, while negotiating with BP on all or part of a deal involving Brilacidin (or entire company)?
4. Could we be witnessing a combination of 2 & 3?
IMO...we will see $2.00 (and likely much more) before and if ever, we see $0.20 again
...of course all IMO
Glad to know your hanging in there.
Also the fact that the trial is ongoing provides us wiith the evidence that Brilacidin is working, just don't know how well yet.
Good day to round up a few had some odd numbers I wanted to level off.
Congress, Biden, passing out and printing money like confetti, soo it will become worthless.
the next 3 dp70 prediction after this are doozies: dp70 said, Feb 16 – IPIX/B gain recognition. This may not be in the form of PR but positive results could start to be seen by those with access to the participants. Increase in sp and value of company could be seen.
"NT 10-Q Notification of inability to timely file 2021-02-17"
News continues:
part of 17th
10-Q Quarterly report 2021-02-22
You didn't get the memo, about yesterday:
dp70 said Feb 9th: All dates posted have an influence of +/- 1 day (weekends excluded as news doesn’t typically come out on weekends).
Feb 12 – possible sp increase with Venus aspect to Venus/Jupiter. More news articles being found about IPIX and B.
News prediction:
"SC 13G Statement of acquisition of beneficial owners... 2021-02-11"
Feb 16 – IPIX/B gain recognition. This may not be in the form of PR but positive results could start to be seen by those with access to the participants. Increase in sp and value of company could be seen.
"NT 10-Q Notification of inability to timely file 2021-02-17"
News continues:
part of 17th
10-Q Quarterly report 2021-02-22
Very close to the date dp70 suggested this: "Feb 28 – possible news about status of trial and possible news regarding foreign trial or dealings with foreigners regarding B. (Mars in 9th house rules publications, dealings with foreign countries). The money prospects of the company steadily increase through March which could be in the form of grants, collaborations, increase in stockholders."
Rember she also said it can be 1 day before or after.
NEW INVESTORS DO NOT PANIC!
I'm Getting cleaed out!
Seriously, its a game people play with otc stock. We just got very good news, that was released in the 10Q (quarterly report) have no idea how they manipulate the price so much but, Brilicidin obviously hasn't had a failed trial or the FDA would have ended the trial and the Pharmaceutical lournals would have trashed us, just have to wait and see after the smoke clears.
News from the 10 Q"
In January 2021, the FDA designated as a Fast Track development program the investigation of Brilacidin for the treatment for COVID-19.
In February 2021, the clinical trial of Brilacidin for treating hospitalized patients with COVID-19 in the United States and Russia began with patients being recruited to the study.
Business Development and Licensing
The Company is actively engaged in business development and licensing initiatives with multiple specialty and global pharmaceutical companies. From time to time, the Company may be party to various indications of interest and term sheets and participate in preliminary discussions and negotiations regarding potential licensing or partnership arrangements. It remains the Company’s primary objective to complete licensing deals, territorial and/or global, to provide access to non-dilutive capital to advance clinical assets forward in the most expeditious and cost-effective manner. The Company can make no assurance that partnerships will occur but is committed toward executing on these potential alliance and partnership opportunities.
In July 2019, the Company entered into a license agreement with Alfasigma, granting Alfasigma the worldwide right to develop, manufacture and commercialize rectally administered Brilacidin for UP/UPS. The license agreement provides Alfasigma with a right of first refusal for Brilacidin for the treatment of more extensive forms of inflammatory bowel disease (IBD), such as ulcerative colitis and Crohn’s disease, as well as a right of first negotiation for Brilacidin in other gastrointestinal indications. In January 2021, Alfasigma notified the Company that the Phase 1 study for the treatment of UP/UPS using Brilacidin in a proprietary Alfasigma formulation was successfully completed. Planning for a Phase 2 clinical trial is underway. The Company is eligible to receive $24 million in upfront and milestone payments, and a 6 percent royalty (net sales) upon the successful marketing of Brilacidin for UP/UPS
Bet there were a lot of stop losses dwn there. Didn't they just create another gap? We haven't closed the Gap "up" to $4.93 yet? Will that be next?